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Th erapeutic drug monitoring seems to be an important 
new aspect in the treatment of patients with rheumatic 
diseases. Th is is argued by Ducourau and colleagues [1] 
in the previous issue of Arthritis Research & Th erapy. In a 
retrospective study of 17 patients with rheumatoid 
arthritis and 91 patients with spondyloarthritis, the 
authors measured trough serum inﬂ iximab levels and 
antibodies toward inﬂ iximab at each visit. Antibodies 
against inﬂ iximab were detected in 21 patients (19%), and 
the median detection time was 3.7 months. In the larger 
group of patients with spondyloarthritis, inﬂ iximab levels 
were only 1.6 mg/L in those with antibodies and 
15.8 mg/L in those without antibodies (P <0.001), and the 
same pattern was found in the smaller rheumatoid 
arthritis group. In addition, patients with antibodies used 
methotrexate less often and infusion reactions occurred 
more often in the antibody-positive patients (52% versus 
1%). We believe that this is an adequately performed but 
retrospective study that does not show exciting new data 
but that does conﬁ rm the clinical relevance of measuring 
serum levels and anti-drug antibodies in patients treated 
with biologicals.
Immunogenicity, the ability to provoke an immune 
response against a foreign protein, results in suboptimal 
drug levels and is one of the reasons for a lack of clinical 
response. In patients with an immunogenic reaction 
against a biological, drug levels are less likely to be in the 
therapeutic range and the treatment eﬀ ect is far from 
optimal, especially when there is no drug present in the 
serum [1,2].
In the last decade, evidence of the detrimental eﬀ ect of 
this immunogenicity has risen signiﬁ cantly [2-5]. It has 
been documented that the presence of anti-drug 
antibodies is associated with drug levels below the 
therapeutic range, or even with absent drug levels, and 
thus with poor clinical outcome. In addition, anti-drug 
antibodies have been associated with adverse events; for 
example, in inﬂ iximab-treated patients, infusion reac-
tions, which can be serious and life-threatening, occur 
more often in patients who have developed anti-inﬂ ixi mab 
antibodies [3]. Recently, an increased risk of thrombo-
embolic events in patients with an immunogenic reaction 
against biologicals was also suggested [6].
Th e extent to which these eﬀ ects of immunogenicity 
occur relies on several aspects related to the patient, the 
drug, and detection: the dose, frequency, and adminis-
tration route of the drug; the timing of the serum 
sampling; and the complexity of measuring anti-drug 
antibodies. Diﬀ erent assays for the measurement of anti-
drug antibodies are available, but these assays have their 
own advantages and disadvantages [7]. Measuring serum 
drug concentrations is less complex but preferably should 
be done in trough samples.
Th e use of concomitant medication such as metho-
trexate, azathioprine, and prednisone inﬂ uences the 
formation of anti-drug antibodies [8]. Th e incidence of 
anti-drug antibodies is lower in patients taking conco-
mitant immunosuppressive medication, and, as a result, 
more patients have drug levels in the therapeutic range 
and a better treatment response.
Given the variation in pharmacokinetics and its clinical 
relevance observed in patients treated with immunogenic 
drugs (generally with high costs), it is remarkable that 
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In the previous issue of Arthritis Research & Therapy, 
Ducourau and colleagues report that they 
retrospectively detected anti-infl iximab antibodies 
in 21% of patients with rheumatic diseases. Patients 
with anti-infl iximab antibodies had lower serum drug 
concentrations. These fi ndings contribute to the 
existing evidence of immunogenicity of biologicals 
and its clinical relevance. We argue for therapeutic drug 
monitoring to optimize treatment response.
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serum drug levels are not measured routinely in these 
patients. Additionally, in patients with drug levels below 
the therapeutic range, the detection of antibody forma-
tion could reveal the reason for these low drug levels.
Although the eﬀ ects of immunogenicity have become 
widely studied for inﬂ iximab and adalimumab, 
comparable studies for other biologicals are lacking. In 
contrast, reported frequencies of antibodies to etanercept 
are lower and these antibodies might not be directed to 
the tumor necrosis factor-binding side but to the hinge 
region of the molecule and therefore are non-neutralizing 
[9,10]. Nevertheless, to verify whether drug levels are in 
the therapeutic range, it seems important to measure at 
least serum drug concentrations in patients using 
biologicals. Recently, it was shown that patients with the 
lowest trough etanercept concentrations are more often 
non-responders but that patients with the highest 
etanercept levels are more often responders [11].
In conclusion, immunogenicity certainly does play a 
role in the treatment of biological therapeutics. Apart 
from the issue of an elevated risk of side eﬀ ects, the 
ﬁ nding of antibodies against a biological and low or 
absent drug levels is important and clinically relevant 
since it is related to a low or even absent biological 
response. Although measurements of antibodies and 
trough serum drug concentrations are not widely 
available (particularly for the new biological therapeutics) 
and additional research questions need to be resolved, 
the evidence that these measurements are clinically 
relevant for individual patients is gradually and 
consistently growing. In our opinion, the time has come 
to start therapeutic drug monitoring in patients with 
biological therapies.
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